Kiniksa Pharmaceuticals Ltd (KNSA NASDAQ) stock market data APIs
$56.9658
0.46(0.8%)
as of May 5, 2026
Try our APIs with
free plan!
Kiniksa Pharmaceuticals Ltd Financial Data Overview
Price chart is built with
Anychart
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prev. Close
56.9658
Open
57.4308
High
58.019
Low
55.8447
52 wk Range
24.85-58.2
Market Cap
4 365 M
P/E Ratio
62.3517
Shares Outstanding
46 303 K
Revenue
754 M
EPS
0.27
Beta
0.172
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kiniksa Pharmaceuticals Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kiniksa Pharmaceuticals Ltd data using free add-ons & libraries
Get Kiniksa Pharmaceuticals Ltd Fundamental Data
Kiniksa Pharmaceuticals Ltd Fundamental data includes:
- Net Revenue: 754 M
- EBITDA: 94 814 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kiniksa Pharmaceuticals Ltd Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-05-05
- EPS/Forecast: 0.324
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kiniksa Pharmaceuticals Ltd News
New
Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance
Kiniksa Pharmaceuticals International, plc reported past first-quarter 2026 results with revenue of US$214.27 million and net income of US$22.59 million, alongside basic earnings per share from contin...
Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) is one of the best drug stocks to buy according to analysts. Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced its fiscal Q1 2...
Exploring High Growth US Tech Stocks This April 2026
The United States market has shown impressive growth, with a 28% increase over the past year despite remaining flat last week, and earnings are projected to grow by 16% annually. In this context, iden...
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ...
This article first appeared on GuruFocus. ARCALYST Revenue: $214.3 million in Q1 2026, a 56% year-over-year increase. Full-Year Revenue Guidance: Raised to $930 million to $945 million from previous ...
Get Kiniksa Pharmaceuticals Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
